Cargando…
Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798802/ https://www.ncbi.nlm.nih.gov/pubmed/35117137 http://dx.doi.org/10.21037/tcr.2019.06.43 |
| _version_ | 1784641901987627008 |
|---|---|
| author | Tremont-Lukats, Ivo W. Teh, Bin S. |
| author_facet | Tremont-Lukats, Ivo W. Teh, Bin S. |
| author_sort | Tremont-Lukats, Ivo W. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8798802 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87988022022-02-02 Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial Tremont-Lukats, Ivo W. Teh, Bin S. Transl Cancer Res Editorial Commentary AME Publishing Company 2019-12 /pmc/articles/PMC8798802/ /pubmed/35117137 http://dx.doi.org/10.21037/tcr.2019.06.43 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
| spellingShingle | Editorial Commentary Tremont-Lukats, Ivo W. Teh, Bin S. Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial |
| title | Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial |
| title_full | Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial |
| title_fullStr | Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial |
| title_full_unstemmed | Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial |
| title_short | Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial |
| title_sort | lomustine and temozolomide for newly diagnosed glioblastoma with methylated mgmt promoter: lessons from the ceteg/noa-09 trial |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798802/ https://www.ncbi.nlm.nih.gov/pubmed/35117137 http://dx.doi.org/10.21037/tcr.2019.06.43 |
| work_keys_str_mv | AT tremontlukatsivow lomustineandtemozolomidefornewlydiagnosedglioblastomawithmethylatedmgmtpromoterlessonsfromthecetegnoa09trial AT tehbins lomustineandtemozolomidefornewlydiagnosedglioblastomawithmethylatedmgmtpromoterlessonsfromthecetegnoa09trial |